Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that CS43158 has been approved by China’s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of acute myeloid leukemia (AML), advancing a multi‑target protein kinase inhibitor designed to simultaneously block driver oncogenic pathways and bypass‑activated drug‑resistance pathways.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Action | Approval to initiate clinical trials (IND) |
| Product | CS43158 – multi‑target protein kinase inhibitor |
| Indication | Acute myeloid leukemia (AML) |
| Announcement Date | 13 Oct 2026 |
| Sponsor | Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) |
| Next Steps | Clinical trial initiation; phase, sites and timelines Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: CS43158, a multi‑target protein kinase inhibitor independently developed by Chipscreen Biosciences.
- Dual‑Action Concept: Simultaneously covers both the driving oncogenic pathways and the bypass‑activated drug‑resistance pathways of AML – targeting primary driver mutations while overcoming secondary resistance in a single agent.
- FLT3 Mutation Coverage: Demonstrates potent inhibitory activity against FLT3 wild‑type overexpression, FLT3‑ITD and FLT3‑TKD, among other common clinical resistance mutations.
- Microenvironment Blockade: Inhibits abnormal activation of non‑FLT3‑mediated cytokine‑ and growth factor‑related signaling in the bone marrow microenvironment, comprehensively blocking non‑FLT3‑dependent tumor cell survival and proliferation pathways.
- Resistance‑Overcoming Rationale: Through synergistic blockade of the core FLT3‑driven pathway and multiple bypass resistance pathways, CS43158 is designed to further enhance anti‑tumor activity versus existing therapies, overcome or delay the emergence of FLT3 inhibitor resistance, and achieve longer‑term therapeutic benefit.
Resistance Coverage Profile
| Target / Pathway | Activity |
|---|---|
| FLT3 wild‑type overexpression | Potent inhibition |
| FLT3‑ITD | Potent inhibition |
| FLT3‑TKD | Potent inhibition |
| Non‑FLT3 cytokine / growth factor signaling (bone marrow microenvironment) | Inhibition of abnormal activation |
| Clinical stage | IND approved; trial phase Not disclosed |
Market Impact & Outlook
- AML Resistance Challenge: FLT3‑mutated AML remains one of the most aggressive leukemia subtypes; although FLT3 inhibitors have improved outcomes, acquired resistance via secondary mutations and bypass signaling is a near‑universal obstacle – the precise gap CS43158’s dual‑pathway design addresses.
- Microenvironment‑Aware Strategy: By additionally targeting non‑FLT3‑mediated survival signals in the bone marrow niche, CS43158 pursues a broader resistance‑proofing approach than single‑pathway FLT3 inhibitors.
- Chipscreen Oncology Expansion: The IND clearance adds a first‑in‑pipeline hematology‑oncology asset to Chipscreen Biosciences (SHA: 688321), extending the company’s small‑molecule discovery engine – built on its chemical genomics platform – into the large‑molecule‑adjacent targeted kinase space for blood cancers.
- China AML Burden: With a substantial and aging AML patient population in China and limited next‑generation options for relapsed/refractory FLT3‑mutated disease, an NMPA‑cleared resistance‑overcoming candidate carries significant domestic clinical and commercial relevance.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial progression, regulatory timelines and therapeutic potential of CS43158. Actual results may differ materially due to risks including early‑phase safety and efficacy outcomes, resistance dynamics in patients, and evolving NMPA review requirements.-Fineline Info & Tech
